STOCK TITAN

Schedule 13G: Gates Capital Reports 12.79M NEOG Shares (5.9%)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Gates Capital and related entities report beneficial ownership of 12,793,941 shares of Neogen Corporation common stock, equal to 5.9% of the 217,205,186 shares outstanding as of June 30, 2025. The filing lists Gates Capital Management, L.P.; Gates Capital Management GP, LLC; Gates Capital Management, Inc.; and Jeffrey L. Gates as joint reporting persons, each disclosing shared voting and dispositive power over the same 12,793,941 shares and no sole voting or dispositive power. The statement affirms the shares were acquired in the ordinary course of business and not to influence control of the issuer. The filing includes a joint filing agreement signed August 14, 2025.

Positive

  • Material, transparent disclosure of a 5.9% stake (12,793,941 shares) meeting SEC reporting requirements
  • Joint filing agreement and signatures provide clear accountability among reporting persons
  • Certification states holdings were acquired in the ordinary course of business and not to change control

Negative

  • Shared voting power across entities indicates consolidated influence even though no sole power is claimed
  • Potential for future activism remains since a 5.9% position is large enough to support engagement or nominations

Insights

TL;DR: A 5.9% stake is material and could attract investor attention but does not indicate control; monitor for further amendments.

The filing shows Gates Capital and affiliated entities hold a non‑controlling yet material stake in Neogen (NEOG). At 12.8 million shares and 5.9% of outstanding stock, this position exceeds the 5% disclosure threshold, signaling the firm considers this a significant economic interest. Shared voting and dispositive power across the reporting persons suggests centralized decision-making within the Gates group rather than fragmented ownership. The certification states the holdings are in the ordinary course of business and not intended to change control, which reduces immediate governance change risk. Investors should note the position size relative to free float and watch for Schedule 13D amendments or proxy activity that would signal activist intentions.

TL;DR: Joint filing discloses material ownership and centralized voting; no explicit control intent declared.

The disclosure is standard for an investment adviser and related entities acting as a group. All reporting persons disclose identical shared voting and dispositive power, and they executed a joint filing agreement, establishing joint responsibility for filings. The explicit certification that the stake was not acquired to influence control is legally relevant but not dispositive of future actions. From a governance perspective, a combined 5.9% stake gives the group standing to engage with management, request information, or nominate directors if they choose, though the filing currently indicates passive intent. Continued monitoring of amendments or communications is warranted to assess any shift toward active engagement.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Gates Capital Management, L.P.
Signature:/s/ Jeffrey L. Gates
Name/Title:Jeffrey L. Gates- President
Date:08/14/2025
Gates Capital Management GP, LLC
Signature:/s/ Jeffrey L. Gates
Name/Title:Jeffrey L. Gates- President
Date:08/14/2025
Gates Capital Management, Inc.
Signature:/s/ Jeffrey L. Gates
Name/Title:Jeffrey L. Gates- President
Date:08/14/2025
Jeffrey L. Gates
Signature:/s/ Jeffrey L. Gates
Name/Title:Jeffrey L. Gates
Date:08/14/2025
Exhibit Information

EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. DATE: August 14, 2025 Gates Capital Management, L.P. By: Gates Capital Management GP, LLC, its general partner By: Gates Capital Management, Inc., its managing member By: /s/ Jeffrey L. Gates Name: Jeffrey L. Gates Title: President Gates Capital Management GP, LLC By: Gates Capital Management, Inc., its managing member By: /s/ Jeffrey L. Gates Name: Jeffrey L. Gates Title: President Gates Capital Management, Inc. By: /s/ Jeffrey L. Gates Name: Jeffrey L. Gates Title: President Jeffrey L. Gates By: /s/ Jeffrey L. Gates

FAQ

How many Neogen (NEOG) shares does Gates Capital report owning?

The filing discloses 12,793,941 shares, representing 5.9% of Neogen's common stock outstanding as of June 30, 2025.

Do the reporting persons claim control of Neogen (NEOG)?

No. The filing states the shares were acquired in the ordinary course of business and not to change or influence control of the issuer.

Who are the reporting persons in this Schedule 13G for NEOG?

The reporting persons are Gates Capital Management, L.P.; Gates Capital Management GP, LLC; Gates Capital Management, Inc.; and Jeffrey L. Gates.

What voting and dispositive powers are reported?

Each reporting person discloses 0 sole voting/dispositive power and 12,793,941 shares of shared voting and shared dispositive power.

When was the Schedule 13G signed?

The joint filing agreement and signatures are dated August 14, 2025.
Neogen Corp

NASDAQ:NEOG

NEOG Rankings

NEOG Latest News

NEOG Latest SEC Filings

NEOG Stock Data

2.46B
215.48M
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
LANSING